Orion OYJ (OTCMKTS:ORINY) Shares Gap Down - Here's Why

Key Points

• Orion OYJ's share price dropped significantly, opening at $36.40 after closing at $41.48, marking a 12.2% decline.
• The company reported a net margin of 22.61% and a return on equity of 38.68% for its last quarter, which saw a revenue of $472.57 million.
• Orion OYJ develops and markets various pharmaceuticals, including treatments for prostate cancer and Parkinson's disease, and is active in multiple international markets.

Orion OYJ Unsponsored ADR (OTCMKTS:ORINY - Get Free Report) gapped down prior to trading on Thursday . The stock had previously closed at $41.48, but opened at $36.40. Orion OYJ shares last traded at $36.40, with a volume of 127 shares traded.

Orion OYJ Trading Up 4.7%

The company has a market cap of $10.76 billion, a PE ratio of 25.93 and a beta of 0.10. The company has a current ratio of 1.86, a quick ratio of 1.05 and a debt-to-equity ratio of 0.15. The stock has a 50 day moving average price of $38.04 and a 200 day moving average price of $32.27.

Orion OYJ (OTCMKTS:ORINY - Get Free Report) last released its earnings results on Friday, July 18th. The company reported $0.33 EPS for the quarter. The company had revenue of $472.57 million during the quarter. Orion OYJ had a return on equity of 38.68% and a net margin of 22.61%. Sell-side analysts predict that Orion OYJ Unsponsored ADR will post 1.18 EPS for the current fiscal year.

About Orion OYJ

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.